Segui
Professor Steven Boyages
Professor Steven Boyages
The University of Sydney
Email verificata su wsahs.nsw.gov.au
Titolo
Citata da
Citata da
Anno
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
A Keech, RJ Simes, P Barter, J Best, R Scott, MR Taskinen, P Forder, ...
Lancet 366 (9500), 1849, 2005
40592005
on behalf of the FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study …
A Keech, RJ Simes, P Barter, J Best, R Scott, MR Taskinen
Lancet 366, 1849-61, 2005
2112*2005
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate …
R Scott, R O'Brien, G Fulcher, C Pardy, M d'Emden, D Tse, MR Taskinen, ...
Diabetes care 32 (3), 493-498, 2009
5982009
On behalf of the FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a pre-specified analysis of a …
K Rajamani, PG Colman, LP Li
Lancet 373, 1780-8, 2009
402*2009
Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.
R Moses, R Slobodniuk, S Boyages, S Colagiuri, W Kidson, J Carter, ...
Diabetes care 22 (1), 119-124, 1999
3651999
Acromegaly. Clinical and biochemical features in 500 patients.
S Ezzat, MJ Forster, P Berchtold, DA Redelmeier, V Boerlin, AG Harris
Medicine 73 (5), 233, 1994
3351994
The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults
RC Cuneo, S Judd, JD Wallace, D Perry-Keene, H Burger, S Lim-Tio, ...
The Journal of Clinical Endocrinology & Metabolism 83 (1), 107-116, 1998
3291998
GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety
R Abs, BÅ Bengtsson, E Hernberg‐Ståhl, JP Monson, JP Tauber, P Wilton, ...
Clinical Endocrinology 50 (6), 703-713, 1999
3141999
Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide: Results of the International Multicenter Acromegaly Study Group
ML Vance, AG Harris
Archives of Internal Medicine 151 (8), 1573, 1991
3041991
Long term treatment of 189 acromegalic patients with the somatostatin analog octreotide: results of the International Multicenter Acromegaly Study Group
H Ag
Arch Intern Med 151, 1573-1578, 1991
3041991
A systematic review of chronic disease management
N Zwar, M Harris, R Griffiths, M Roland, S Dennis, G Powell Davies, ...
Australian Primary Health Care Research Institute (APHCRI), 2006
2762006
Clinical review 49: iodine deficiency disorders
SC Boyages
The Journal of Clinical Endocrinology & Metabolism 77 (3), 587-591, 1993
2691993
Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology
JR Burgess, P Tucker
Thyroid 16 (1), 47-53, 2006
2432006
Relationship of Type 2 diabetes to the prevalence, incidence and progression of age‐related hearing loss
P Mitchell, B Gopinath, CM McMahon, E Rochtchina, JJ Wang, ...
Diabetic Medicine 26 (5), 483-488, 2009
2112009
Guideline: Calcium supplementation in pregnant women
World Health Organization
World Health Organization, 2013
1902013
Topical iodine-containing antiseptics and neonatal hypothyroidism in very-low-birthweight infants
P Smerdely, SC Boyages, D Wu, G Leslie, E John, A Lim, K Waite, ...
The Lancet 334 (8664), 661-664, 1989
1711989
Endemic goitre in central China caused by excessive iodine intake
L Mu, Q Chengyi, Q Qidong, J Qingzhen, CJ Eastman, JK Collins, L Derun, ...
The lancet 330 (8553), 257-259, 1987
1671987
Cochlear origin of hearing loss in MELAS syndrome
CM Sue, LJ Lipsett, DS Crimmins, CST DipAud, SC Boyages, ...
Annals of neurology 43 (3), 350-359, 1998
1591998
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with …
R Scott, R O’Brien, G Fulcher, C Pardy, M d’Emden, D Tse, MR Taskinen, ...
Diabetes Care 32 (3), 493-8, 2009
1522009
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators
R Scott, R O'Brien, G Fulcher, C Pardy, M D'Emden, D Tse, MR Taskinen, ...
Effects of fenofibrate treatment on cardiovascular disease risk in 9, 0
152*
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20